{"id":"NCT01521923","sponsor":"UCB Pharma","briefTitle":"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis","officialTitle":"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate for Inducing and Sustaining Clinical Response in the Treatment of DMARD-Naïve Adults With Early Active Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-01","primaryCompletion":"2015-07","completion":"2015-09","firstPosted":"2012-01-31","resultsPosted":"2017-01-10","lastUpdate":"2018-07-31"},"enrollment":359,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"Certolizumab Pegol + Methotrexate (MTX)","otherNames":["Cimzia","CZP","MTX"]},{"type":"BIOLOGICAL","name":"Placebo + Methotrexate (MTX)","otherNames":["MTX"]}],"arms":[{"label":"CZP 200 mg Q2W + Methotrexate","type":"EXPERIMENTAL"},{"label":"CZP 200 mg Q4W + Methotrexate","type":"EXPERIMENTAL"},{"label":"Placebo + Methotrexate","type":"PLACEBO_COMPARATOR"}],"summary":"This study is intended to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in combination with Methotrexate (MTX) for sustaining clinical response achieved in study RA0055 Period 1 \\[NCT01519791\\]. Subjects entering this study RA0055 Period 2 achieved sustained Low Disease Activity at Week 52 in study RA0055 Period 1.","primaryOutcome":{"measure":"Percentage of Subjects With Disease Activity Score [Erythrocyte Sedimentation Rate] (DAS28 [ESR]) <= 3.2 at Week 104 in RA0055 Period 2 Without Flaring","timeFrame":"Week 104 in RA0055 Period 2","effectByArm":[{"arm":"CZP+MTX / PBO+MTX (Full Analysis Set [FAS])","deltaMin":39.2,"sd":null},{"arm":"CZP+MTX / CZP Q4W+MTX (Full Analysis Set)","deltaMin":53.2,"sd":null},{"arm":"CZP+MTX / CZP Q2W+MTX (Full Analysis Set)","deltaMin":48.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"=0.112"},{"comp":"OG000 vs OG001","p":"=0.041"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":178,"countries":["United States","Argentina","Australia","Austria","Belgium","Canada","Colombia","Czechia","France","Germany","Hungary","Ireland","Italy","Mexico","Monaco","Netherlands","Poland","Romania","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["27165179","28666080"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":66},"commonTop":["Nasopharyngitis","Hypercholesterolaemia","Urinary tract infection","Pharyngitis","Latent tuberculosis"]}}